AbbVie's Mirvetuximab Soravtansine Shows 51.9% Response Rate in Ovarian Cancer

AbbVie's Mirvetuximab Soravtansine Shows 51.9% Response Rate in Ovarian Cancer

Luisa Fernandez
2 min read

AbbVie Reports Positive Results from Phase II Trial of Mirvetuximab Soravtansine in Ovarian Cancer

AbbVie has revealed encouraging findings from the Phase II PICCOLO trial of mirvetuximab soravtansine, exhibiting a 51.9% objective response rate in heavily pre-treated ovarian cancer patients. The trial, focused on individuals with high folate receptor-alpha and platinum-sensitive ovarian cancer, also showcased a median duration of response of 8.25 months. The drug's safety profile remained consistent with prior studies, with no new concerns arising. This medication, already approved in the US for addressing platinum-resistant ovarian cancer under the brand name ELAHERE, is presently under review by the European Medicines Agency. Additionally, AbbVie is exploring the drug in combination with bevacizumab in the ongoing Phase III GLORIOSA trial.

Key Takeaways

  • Mirvetuximab soravtansine exhibited a 51.9% objective response rate in ovarian cancer patients.
  • The Phase II PICCOLO trial assessed the drug in heavily pre-treated, platinum-sensitive ovarian cancer patients.
  • The primary endpoint of the trial was met, with a median duration of response of 8.25 months.
  • The safety profile of the drug was consistent with previous studies, with no new concerns.
  • Mirvetuximab soravtansine, marketed as ELAHERE, is already approved in the US for platinum-resistant ovarian cancer.


AbbVie's favorable Phase II results for mirvetuximab soravtansine in platinum-sensitive ovarian cancer could profoundly influence treatment protocols and patient outcomes. The high response rate and manageable safety profile imply potential expansion of the drug's indications, impacting healthcare providers and pharmaceutical markets. This development may also have an effect on AbbVie's stock value and competitive positioning in the oncology sector. Successful integration into clinical practice in the long term could redefine standards of care, while regulatory approval in Europe could extend its market reach. Ongoing trials, such as the Phase III GLORIOSA, will further elucidate its efficacy and market potential.

Did You Know?

  • Mirvetuximab Soravtansine: This is a targeted therapy drug used in treating ovarian cancer. It is an antibody-drug conjugate (ADC) that combines a monoclonal antibody (mirvetuximab) with a potent cytotoxic agent (soravtansine). The antibody targets the folate receptor alpha, which is often overexpressed in various cancer cells, delivering the cytotoxic payload directly to the cancer cells, thereby minimizing damage to normal cells.
  • Objective Response Rate (ORR): This measure is used in clinical trials to assess the effectiveness of a cancer treatment. It is defined as the percentage of patients whose tumor size is reduced by a predefined amount for a minimum period of time, indicating that the treatment has a measurable effect on the disease.
  • Platinum-Sensitive Ovarian Cancer: This term describes ovarian cancers that respond to platinum-based chemotherapy (such as cisplatin or carboplatin). These cancers typically recur more than six months after initial treatment with platinum-based chemotherapy, indicating that the cancer cells are still sensitive to the effects of platinum.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings